Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded without agreement
Manufacturer:
Duchesnay Inc.
Indication:
Dyspareunia and/or Vaginal Dryness
Last updated:
April 14, 2023
Status:
Concluded without agreement
Manufacturer:
Lupin Pharma Canada Ltd.
Indication:
Postmenopausal vulvovaginal atrophy
Last updated:
April 14, 2023
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Diabetic Macular Edema
Last updated:
April 11, 2023
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Atopic dermatitis
Last updated:
April 4, 2023
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Medullary thyroid cancer (MTC), rearranged during transfection (RET)-mutant, in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease
Last updated:
March 31, 2023
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Differentiated thyroid carcinoma (DTC), Rearranged during transfection (RET) fusion-positive, in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) monotherapy treatment following prior treatment with sorafenib and/or lenvatinib
Last updated:
March 31, 2023
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Metastatic RET fusion-positive non-small cell lung cancer (NSCLC), Monotherapy for the treatment of adult patients
Last updated:
March 31, 2023
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Schizophrenia in Adults
Last updated:
March 28, 2023
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma
Last updated:
March 23, 2023
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, in adult patients, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options
Last updated:
March 16, 2023